GlassScriptPhysician profile
Subbarao Bhimani
NPI 1164482444
$1,679.07
in general payments reported to CMS, 2019-2025
13 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.73 · 2021: $249 · 2022: $382 · 2023: $512 · 2024: $311 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,003.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $502.18 | 2023-2025 | Dalvance, Avycaz, Teflaro |
| Glaxosmithkline, LLC. | $374.28 | 2021-2023 | Shingrix |
| Alexion Pharmaceuticals, INC. | $132.30 | 2022 | |
| Medtronic, INC. | $125.00 | 2022 | |
| Boston Scientific Corporation | $124.10 | 2021 | |
| Corium, LLC | $118.39 | 2023 | Adlarity |
| Intuitive Surgical, INC. | $75.96 | 2023 | Da Vinci Surgical System |
| Janssen Pharmaceuticals, INC | $64.52 | 2019-2023 | Xarelto |
| Mallinckrodt Hospital Products INC. | $61.81 | 2024 | Terlivaz |
| Vifor Pharma, INC. | $29.51 | 2023 | Veltassa, Korsuva |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.12 | 2025 | Caplyta |
| Neurelis, INC. | $23.60 | 2023 | Valtoco |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subbarao Bhimani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.